Community Member
2 years ago✅ The FDA just approved capivasertib plus fulvestrant (Faslodex) as a treatment option for patients with HR+/HER2- locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations. Learn more about the approval and what it could mean for you: https://www.cancernetwork.com/view/fda-approves-capivasertib-plus-fulvestrant-in-advanced-hr-her2-breast-cancer
Accepted Answer
This new FDA approval represents an important advancement for patients with HR+/HER2- breast cancer who have specific genetic alterations, as it provides another targeted treatment option when the cancer has progressed. Having additional therapies available can offer hope and potentially better outcomes for those who qualify based on their tumor's specific characteristics.
3+ patients found this helpful
Community Member
6 months agoI have that
Community Member
6 months ago🌬️🤍 @ Rebecca Z
Community Member
6 months agoThis is what I have. I'll start taking Capivaserib (Truqap) very soon.
Community Member
6 months agoI don't get this. This was out by the moderate was posted Nov 17 2023 and there is only 4 posts? What an I missing? I mean I see other responses in this site that are more responsive. Also I'm on some other quasi support on line sites and they seem more responsive. I dunno. I like this site for the support part but the integrative communication seems a bit off to me. 🤷
Community Member
6 months agoSince truqap was just approved, is unlikely that many patients have completed a full treatment cycle (4 mos) of it yet .. maybe that would explain the lack of a more thorough discussion re this medication /protocol? 🤷🏼♀️
Community Member
6 months agoThat could very well be, Melanie. I feel a little like a guinea pig 🥴, So far, things are going pretty well. I have diarrhea, but I've had worse with food poisoning. I don't have a rash. My mouth is extremely dry and food tastes like wall paper paste. One day at a time.
Community Member
6 months agoI haven’t experienced any side effects from Zometa. Yay!
Community Member
2 months agoThis new FDA approval represents an important advancement for patients with HR+/HER2- breast cancer who have specific genetic alterations, as it provides another targeted treatment option when the cancer has progressed. Having additional therapies available can offer hope and potentially better outcomes for those who qualify based on their tumor's specific characteristics.
New to the community?
Create an account to connect with others navigating cancer.
© 2025 Outcomes4Me Inc. All rights reserved.